Founded in 2020 under the dynamic and visionary leadership of Mr. Rakesh Sutariya, Zenovel has embarked on a remarkable journey to simplify regulatory complexities while upholding the highest standards of ethical integrity.
In just four years, we have established ourselves as a trusted partner in the healthcare and pharmaceutical sectors, setting new benchmarks of excellence through innovation and unwavering commitment. Our team, a powerhouse of expertise, combines over a decade of collective experience. This unique blend of industry veterans and forward-thinking professionals enables us to anticipate and adapt to emerging trends, helping our clients maintain a competitive edge.
Zenovel’s dedication to excellence and client success has fuelled our expansion across multiple nations, strengthening our global footprint. Our GMP support services, lauded by clients worldwide, exemplify our unwavering commitment to quality and reliability.
With an impressive track record of 332 successful audits for prominent companies, we have consistently nurtured partnerships, built trust, and catalysed transformative growth for our clients. This dedication earned us the prestigious recognition as one ofIndia Pharma Outlook’s Top 10 Pharmaceutical Regulatory Consultants for 2024. This accolade underscores our leadership in the field and reinforces our position as the preferred partner for pharmaceutical and healthcare organizations globally.
At Zenovel, we take pride in our customer-centric approach. We have supported over 50 international clients in achieving their healthcare goals, offering tailored solutions to navigate regulatory landscapes, ensure compliance, and drive innovation.
As we expand our horizons, Zenovel remains steadfast in its commitment to fostering partnerships built on integrity, transparency, and quality. Together, we are shaping the future of pharmaceutical quality control and healthcare—one milestone at a time.
After reaching significant milestones in our journey so far, Zenovel looks forward to an even brighter and more impactful future. Our strategy is rooted in the belief that success is achieved in stages, with each action taken today laying the foundation for future accomplishments.
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.
